1 completed, 1 not yet recruiting, 1 unknown. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
Follow Advanced NSCLC: new trials by email Literature Review of Advanced NSCLC trials Research Report on Advanced NSCLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy Tislelizumab, Anlotinib - Advanced NSCLC | Phase 4 | Not yet recruiting | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | 33 | 2024-07-01 | 2024-04-10 |
| Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). Gene Profile explore - Advanced NSCLC | Phase 4 | Completed | AstraZeneca | 182 | 2022-02-25 | 2025-09-11 |
| Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Endostar(rh recombinant endostatin) plus Docetaxel, Placebo plus Docetaxel - Advanced NSCLC, Recurrent NSCLC | Phase 4 | Unknown | Simcere Pharmaceutical Co., Ltd | 300 | 2008-10-01 | 2010-01-25 |
Carcinoma, Non-Small-Cell Lung (2)
Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2)
Control Groups (1) · Docetaxel (1) · anlotinib (1) · tislelizumab (1)
AstraZeneca (1) · Simcere Pharmaceutical Co., Ltd (1) · The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine (1)
China (2)
Kai LI, professor (1) · Yuankai Shi, PhD (1)